Notice ID: a34ae420984f4554944d04eefaacc755Solicitation
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Active, responses due . Full description on SAM.gov.
Description
See Soliciation Amendments 0001 and 0002.
USAISR's Combat Casualty Care Research Team 1 (CRT-1) requires resupply of its Blood Donor Room on a reoccurring basis in order to satisfy research requirements for blood collection. USAISR currently has three Terumo Trima Accel Blood Collection Systems in operation. These units support numerous research protocols. Various collection sets are used to collect a variety of blood products from donors. The Trima instrument is FDA-approved, but only with the use of original manufacturer-supplied consumable products. These consumables are specific to the instrument and there are no generic substitute products available in the marketplace.
Please note - This is a 100% set-aside for Service-Disabled Veteran-Owned Small Businesses.
See attached complete solicitation for all requirement details and instructions to offerors.
Overview
Agency:
Department of WarDEFENSE HEALTH AGENCY (DHA)
Office:ARMY MED RES ACQ ACTIVITY
Posted:October 23, 2026
NAICS:325413: In-Vitro Diagnostic Substance Manufacturing
Last Updated:Oct 28, 2026
First published:
Last updated on SAM.gov:
PSC:6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES
Set-Aside:Service-Disabled Veteran-Owned Small Business (SDVOSB) Set-Aside (FAR 19.14)
Type:Solicitation
Place of Performance:0, Texas, 78234
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Jeremy McMurry
Secondary Contact
Eric Zampelli
Documents
Files (5)
- Download
Solicitation Amendment - HT942627QE0030002.pdf
2.6 MBAdded in Solicitation version 4Posted - Download
Solicitation Amendment HT942627QE0030002 SF 30.pdf
389 KBAdded in Solicitation version 4Posted - Download
Solicitation Amendment HT942627QE0030001 SF 30.pdf
419 KBAdded in Solicitation version 2Posted - Download
Solicitation Amendment - HT942627QE0030001.pdf
516 KBAdded in Solicitation version 2Posted - Download
Solicitation - HT942627QE003.pdf
1.8 MBAdded in Solicitation version 2Posted
Lifecycle
- 1Version 1Solicitation
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
- 2Version 2Solicitation
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
- 3Version 3Solicitation
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
- 4Version 4SolicitationCurrent
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
THIS IS A SOURCES SOUGHT NOTICE ONLY. This notice does NOT constitute a request for quote (RFQ), request for proposal (RFP), or invitation for bid (IFB). No solicitation is currently available. This Sources Sought is issued solely for information and planning purposes to conduct market research and determine the availability and capability of qualified sources prior to determining the appropriate acquisition strategy. I. General Information - Agency/Office: Department of Veterans Affairs (VA), VA North Texas Health Care System (VANTHCS), 4500 S. Lancaster Rd. Dallas, TX. 75216 - Place of Performance: VA North Texas Health Care System, Pathology and Laboratory Medicine Service (P&LMS), Microbiology Laboratory, Dallas, Texas. - Anticipated NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing - Anticipated PSC: 6550 In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets. The Government is seeking to identify responsible vendors capable of providing Blood Bank Reagents, used to perform patient manual blood typing and serum antibody detection and identification to be used in the Transfusion Medicine Unit, Pathology and Laboratory Medicine Services at VANTHCS. II. Description of Requirement Transfusion Medicine Unit, Pathology and Laboratory Medicine Services (P&LMS) at the VA North Texas Health Care System (VANTHCS), Dallas, TX is seeking blood reagents used to perform patient manual blood typing and serum antibody detection and identification testing used for cross matching blood for transfusions. The contemplated purchase includes, at a minimum: The Contractor shall provide reagent supplies as requested by VANTHCS staff to perform blood bank manual blood typing and serum antibody detection and identification testing used for cross matching blood for transfusions. Estimated Yearly Requirements: Item # Description/Part Number* Qty Unit 1 Z401U, ALBAcyte A1 Cells 52 EA 2 Z406U, ALBAcyte A2 Cells 13 EA 3 Z411U, ALBAcyte B Cells 52 EA 4 Z4411U-1, ALBAcyte IgG Sensitized Cells (weak) 26 EA 5 Z473U, ALBAcyte Antibody ID Panel (16-cell) 7 EA 6 Z482U, ALBAcyte C3 Coated Red Blood Cells 13 EA Period of Performance: Base Year: 05/01/2027-04/30/2028 Option Year 1: 05/01/2028-04/30/2029 Option Year 2: 05/01/2029-04/30/2030 Option Year 3: 05/01/2030-04/30/2031 Option Year 4: 05/01/2031-04/30/2032 Location: The manual testing will be performed in Transfusion Medicine Unit, Pathology & Laboratory Medicine Service, VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216. III. Performance requirements: Performance Requirements: The following are required: Packing and Delivery: All Shipping/Freight Charges will be FOB Destination unless noted otherwise by vendor and communicated to the contracting officer prior to award. The reagents shall be delivered at the time specified when the order is placed. The Contractor will furnish appropriate containers for shipment of the reagents. Vendor must be approved by the FDA and shall provide documentation of approval. Vendor must have a defined Quality plan, and Adequate supplies available. IV. Submission Instructions Interested and capable vendors should submit an electronic capability statement and include the place of manufacture for all reagents listed in the sources sought via email in PDF or Word format by November 5, 2026, by 9:00 AM Central Standard Time. - Teresa Arzola  - Email: Teresa.arzola@va.gov  - Subject line: Sources Sought Blood Bank Reagents VA North Texas HCS  No telephone inquiries will be accepted. Responses received will be used solely for market research and planning purposes to assist the Government in determining an appropriate acquisition strategy (e.g., small business set aside or unrestricted). Submission of a capability statement is voluntary and shall not be construed as a commitment by the Government to issue a solicitation or award a contract, nor will the Government pay for information submitted in response to this Sources Sought. | Market Research | 325413 | No Set-Aside | 10/28/2026 | 11/05/2026 | Dallas, TX | |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | Solicitation | 325412 | No Set-Aside | 10/08/2026 | 10/26/2026 | San Antonio, TX | |
NOTICE OF INTENT TO SOLE SOURCE: The Defense Health Agency – Healthcare Contracting Division – South, intends to award a sole source contract in accordance with RFO FAR 8.104 (Use of Existing Contracts) to INO THERAPEUTICS LLC, to procure delivery of Inhaled Nitric Oxide (iNO) for use at the Department of Medicine. at Brooke Army Medical Center, Fort Sam Houston, Texas. The period of performance is 01 JAN 2027 – 31 DEC 2027, plus four (4) option years. This notice serves to announce the Government’s intent to sole source this requirement and determine if any other sources exist. Interested sources with the demonstrated capability to meet all of the technical requirements outlined in this notice are invited to submit, in writing. Responses must include clear and convincing evidence that competition would be beneficial to the Government and would not be cost or schedule prohibitive. Respondents are responsible for appropriately marking any proprietary information. Responses will not be returned. The contractor shall deliver the following crucial elements: (a) the supply of nitric oxide for inhalation, the pharmaceutical drug essential for the therapy (800 parts per million [PPM]); (b) a specialized Delivery Device that meets the precise criteria outlined in the iNO product label for safe and effective administration, (c) all necessary maintenance and calibration items, accessories, and disposable supplies required for the ongoing operation of the system, and (d) a range of support services, including training, maintenance, pick-up and delivery logistics. This synopsis/notice of intent to sole source is issued in accordance with Federal Acquisition Regulation (FAR) Revolutionary FAR Overhaul (RFO) 5.101 and 12.102 and will be posted for 15 days. Response Due Date: October 22, 2026 by 12:00 PM (CST) Submit to: Contracting Officer: Joe D. Wells at joe.d.wells3.civ@health.mil. . | Market Research | 325412 | No Set-Aside | 10/08/2026 | 10/22/2026 | 0, TX | |
Electrophoresis CPT Sources Sought Notice This notice is for planning purposes only and shall not be considered an invitation for bid, request for quotation, request for proposal, or as an obligation of the government to acquire any products or services. Responses to this notice will be used for informational purposes only. No entitlement to payment of direct or indirect costs from the government will arise as a result from a response to this announcement. No contract will be awarded from this notice. The information requested in this notice will be used to determine if there are sufficient socioeconomic small business concerns that are capable of performing the work described for the requirement. The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office (NCO) 17 is seeking sources for the following procurement: Electrophoresis CPT; Contractor shall provide a fully automated, gel electrophoresis instrument that can perform both serum and urine electrophoresis (SPEP/UPEP), immunofixation (SIFE/UIFE) and Immunotyping (IT) to identify monoclonal and polyclonal gammopathies for the Pathology & Laboratory Medicine Service of the South Texas Veterans Health Care System (STVHCS), Audie L. Murphy Memorial VA Hospital, located at 7400 Merton Minter Blvd., San Antonio, TX 78229. See attached Statement of Work. BACKGROUND South Texas Veterans Health Care System Pathology & Laboratory Medicine Services (P&LMS) 7400 Merton Minter Blvd. San Antonio, TX 78229 DESCRIPTION OF SERVICES The South Texas Veterans Health Care System (STVHCS) has a continued need for Serum and Urine Protein Electrophoresis, IFE, and IT instrumentation. The contractor shall provide a fully automated, gel electrophoresis instrument that can perform both serum and urine electrophoresis (SPEP/UPEP), immunofixation (SIFE/UIFE) and Immunotyping (IT) to identify monoclonal and polyclonal gammopathies. The Sebia instruments Capillarys and Hydrasys have been in use in the STVHCS Chemistry Laboratory 2016. See Price/Cost Schedule and Attachment A within the Statement of Work (SOW) for lists of estimated testing needs. (Quantities are estimates only). See attached SOW for the performance requirements. RESPONSE If interested, please provide the following information in a response: 1. Name of Company 2. Point of Contact; name, phone number and email address 3. SAM UEI # or DUNS number 4. Company socio-economic status (i.e., Small Business, SDVOSB/VOSB) 5. Capability Statement The information provided in a response to this notice may be used in developing an acquisition approach. Interested parties are responsible for adequately marking any proprietary or competitive sensitive information that is provided in a response. Submission Instructions: Interested parties who consider themselves qualified to perform must respond to the notice to be considered by 10:00 AM CST, September 22, 2026. All responses under this Sources Sought Notice must be emailed to Jose.Campa@va.gov. Telephone inquiries will not be accepted or acknowledged and no feedback or evaluations will be provided to companies regarding their submissions. | Market Research | 325413 | No Set-Aside | 09/11/2026 | 09/22/2026 | San Antonio, TX | |
BLOOD BANK COST PER TEST REQUIREMENT | Pre-Solicitation | 325413 | No Set-Aside | 09/04/2026 | 09/08/2026 | - |
Additional Details
Solicitation Number
HT942627QE003
Archive Date
Nov 21, 2026
Office Address
FORT DETRICK, MD, 21702